{
    "nctId": "NCT05150652",
    "briefTitle": "Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",
    "officialTitle": "Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Change in margin status",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed invasive breast cancer, clinically stage I-II.\n* Clinically lymph node negative\n* Eligible for anti-endocrine treatment (per medical oncologist)\n* Postmenopausal women\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Progesterone receptor negativity\n* High grade tumor\n* Synchronous non-breast malignancy\n* Receiving any other investigational agents that could impact the efficacy of this trial regimen\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study\n* Uncontrolled intercurrent illness\n* Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}